

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the tre⦠read more
Healthcare
Biotechnology
21 years
USD
Exclusive to Premium users
$12.25
Price-4.74%
-$0.61
$1.027b
Small
-
Premium
Premium
-6123.8%
EBITDA Margin-6183.4%
Net Profit Margin-6226.9%
Free Cash Flow Margin-6123.8%
EBITDA Margin-6183.4%
Net Profit Margin-6226.9%
Free Cash Flow Margin$7.615m
-2.2%
1y CAGR+1.0%
3y CAGR+3.8%
5y CAGR-$271.599m
-57.2%
1y CAGR-37.1%
3y CAGR-46.6%
5y CAGR-$3.50
-28.9%
1y CAGR-7.6%
3y CAGR-14.4%
5y CAGR$230.472m
$288.217m
Assets$57.745m
Liabilities$22.314m
Debt7.7%
-0.1x
Debt to EBITDA-$271.540m
-64.0%
1y CAGR-2656.1%
3y CAGR-2000.5%
5y CAGR